ANVS Oct 2024 7.500 put
- GlobeNewswire
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
Join Our Investor Call for In-Depth Findings Discussion Efficacy in Early AD Patients Buntanetap showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. Comparable Safety Buntanetap was found to be equally safe in both APOE4 carriers and non-carriers, with no instances of ARIA. MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug p
- GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap. Investor Call Details: Date and Time: June 11, 2024, 4:30pm ET.R
- Zacks
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
